Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861565 | 1.00 | TTR (0.49) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL25046532 | 0.91 | MIF (0.46) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL29861448 | 0.91 | TTR (0.51) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL23458566 | 0.91 | TTR (0.51) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL23458537 | 0.90 | TTR (0.56) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL29861397 | 0.90 | TTR (0.56) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL25046515 | 0.87 | TTR (0.51) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL29861238 | 0.83 | TTR (0.59) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL23458565 | 0.83 | TTR (0.59) | TTRMIFNAALAD2FOLH1NQO1 | |
| SCHEMBL30200914 | 0.81 | TTR (0.58) | TTRMIFNAALAD2FOLH1NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2021110860-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110860-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046947-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | TTR 1071/4885MIF 2775/4885NAALAD2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.